secondary malignancy

Unraveling the Risks: T-Cell Lymphoma After CAR T-Cell Therapy—A Rare but Real Concern

T-cell lymphomas after CAR T-cell therapy are exceedingly rare but significant. This article reviews incidence, mechanisms, diagnostic challenges, and clinical implications to guide vigilance without overshadowing CAR T-cell therapy’s